

# 1H FY2018 Results

Period Ending 31 December 2017



Andrew Harrison  
Managing Director

*27 February 2018*

CAPITOLHEALTH  
LIMITED

# 1. 1H FY18 performance



# Financial performance – 1H FY18

## Profit and Loss summary<sup>1, 2</sup>

	1H FY18 (\$m)	1H FY17 (\$m)
Revenue	56.1	52.7
<b>EBITDA prior to ISI</b>	<b>10.4</b>	<b>5.0</b>
Net ISI losses / (gain) <sup>3,4</sup>	1.6	(0.5)
<b>EBITDA after ISI</b>	<b>8.8</b>	<b>5.5</b>
Borrowing costs	1.8	1.1
Depreciation & amortisation	2.7	2.3
<b>NPBT</b>	<b>4.3</b>	<b>2.0</b>
Tax	1.5	0.0
NPAT (Continuing operations)	2.7	2.0
NPAT (Discontinued operations)	0.2	0.2
<b>Statutory NPAT</b>	<b>2.9</b>	<b>2.2</b>

- Operating revenue of \$54.8m
  - Up 5.1% adjusted for working days or \$2.3m on 1H17
- EBITDA of \$10.4m before one-off transaction costs
  - Underlying EBITDA growth of 100%+
- Acquisition costs related to acquisition of I-rad, Radiology Tasmania, and IDX takeover bid
- Declared interim dividend 0.4cps fully franked
- Substantial increase in underlying EBITDA margin to ~19%

<sup>1</sup> Abridged summary prepared for comparative purposes; refer to Half-year Report for statutory detail

<sup>2</sup> Figures rounded to nearest \$100k; sums subject to rounding differences

<sup>3</sup> ISI – 1H FY18 represent transaction costs related to acquisition of I-rad, Radiology Tasmania, and IDX takeover bid.

<sup>4</sup> ISI – 1H FY17 represent cost related to forfeiture of share options \$1.1m, M7T options valuation adjustment \$0.1m offset by \$1.7m gain in property sale and deferred consideration.

# Financial performance – 1H FY18


Balance Sheet summary <sup>1,2</sup>		
	1H FY18 (\$m)	1H FY17 (\$m)
Cash	85.4	12.6
PP&E	24.1	34.9
Other	28.2	31.4
Intangibles	53.2	130.0
<b>Total Assets</b>	<b>190.9</b>	<b>208.9</b>
Loans & Borrowings	52.6	99.1
Other	18.7	21.6
<b>Total Liabilities</b>	<b>71.3</b>	<b>120.7</b>
<b>Net Assets</b>	<b>119.5</b>	<b>88.2</b>
<i>Net Debt / (cash)</i>	<i>(32.8)</i>	<i>86.5</i>

- Cash balance after acquisitions of \$85.2m (Jan 2018 month end Balance)
- NAB senior facility drawn to \$27.0m, used to fund acquisitions
- \$48.3m unsecured note
  - May 2018 option for early redemption
- Projected net debt after the Integral Diagnostics takeover will be comfortable at ~1.5x EBITDA

<sup>1</sup> Abridged summary prepared for comparative purposes; refer to Half-year Report for statutory detail

<sup>2</sup> Figures rounded to nearest \$100k; sums subject to rounding differences

# Bridge from Underlying to Statutory results (1H FY18)




For personal use only

# Key achievements over the past 12 months

## Key achievements

- ✓ **NSW asset sale completed**
  - Proceeds of \$81.5m received in August 2017 support a strong balance sheet with a net cash position of \$32.8m
- ✓ **Renewed focus on Radiology and Clinicians**
  - long-standing Medical Advisory Committee now reporting directly to the Board of Directors
  - Developing sub-specialty practices and related fellowship programs
  - Increased investment in training and development
- ✓ **Significant uplift in EBITDA margins to ~19%**
  - Reflect organic and acquired growth and right sized cost base
- ✓ **Driving acquisition opportunities**
  - Acquisition of I-rad and Radiology Tasmania completed in February 2018
  - Further acquisitions in the pipeline
  - Opportunity of IDX takeover bid to bring together two highly complementary networks to create a new force in diagnostics in Australia

## Capitol last 12 months price and volume



# Renewed clinical focus

- ✓ Focus on retaining and developing Doctor and clinical resources
- ✓ Fellowship programs in MSK and Body & Comprehensive Cardiac Imaging
- ✓ Sonographer training program
- ✓ Development of sub specialty focussed businesses:  
MSK / Sports Imaging – Imaging at Olympic Park and Body Imaging / Comprehensive Cardiac Imaging Services – Vermont
- ✓ Medical Advisory Committee (MAC) reporting directly to Board of Directors
- ✓ Strong focus on training, education, and professional development through modality committees
- ✓ Large internal and external tele-radiology business
- ✓ Research participation (e.g. Enlitic R&D programs)



## 2. Takeover offer for IDX





# Update on takeover Offer IDX

<b>Offer overview</b>	<ul style="list-style-type: none"> <li>● Offer opened on 14 February 2018</li> <li>● The Offer to acquire all of the ordinary voting shares in Integral is for a consideration of 6.9 fully paid ordinary shares in Capitol and \$0.36 cash for each Integral share</li> </ul>
<b>Benefits and highlights</b>	<ul style="list-style-type: none"> <li>✓ Greater scale and financial strength to capitalise on growth opportunities in the healthcare market, as well as enhanced share liquidity and access to capital markets</li> <li>✓ Diversified geographic and clinical profile, and now including the recently announced \$24.2m acquisition by Capitol of Radiology Tasmania</li> <li>✓ Doctors to benefit from a larger referral network with greater options for continuing professional development, including through the promotion of centres of excellence such as Imaging @ Olympic Park in Melbourne</li> <li>✓ Significant operating savings and efficiencies across duplicated public company costs, head office and administrative functions, as well as potential revenue synergies from improved optimisation of network locations</li> </ul>
<b>Target's Statement</b>	<ul style="list-style-type: none"> <li>● As announced by Integral, Integral's Target's Statement is expected to be lodged by Friday, 2 March 2018</li> <li>● Capitol will review Integral's Target's Statement, including the Independent Expert's Report, and formally respond in due course</li> </ul>

### 3. Future outlook



# Strategic investments

## JV with CITIC & Zhouxin



- Consulting and clinic management
- Option of participating in clinic ownership
- CITIC well placed due to large existing hospital network in China
- Provides platform to leverage growth in Chinese healthcare and emerging private DI market
- Capitol to contribute RMB 3m (~A\$0.6m) for 30% stake in JV, CITIC will hold 60% & Zhouxin 10%
- No further cash contribution expected unless clinic ownership option exercised
- Provides low risk option to growing market not reliant on Australian Government regulation
- Domestic regulatory delays have deferred commencement of operations

### About CITIC Group

- >750,000 employees
- Annual revenue AUD\$737B
- Market Cap AUD\$55.5B
- 160 in global Fortune 500 (2014)

### About Zhouxin Group

- High end health centre owner
- Cardiac MRI specialists
- CITIC has ownership stake



- Continues to make major breakthroughs in applying Deep Learning
  - Chest X-ray Triage - CT Lung Cancer detection – Natural Language Processing (NLP) – Mammography
- Chest X-ray Data Testing, Calibration and Trials with major companies in China & Japan
- Collaboration on CT lung cancer with a major research institution and commercial customers in US
- Leading medical data inventory from international sources
- Several patent opportunities and incremental regulatory approval strategy
- Won €1m prize for best start-up awarded by Apple founder Steve Wozniak
- Planning Australia TGA registration for post hoc quality assurance use
- Currently considering opportunities to crystallise value for Capitol


### About the Enlitic investment

- Ownership 25% undiluted, 1 board seat
- Collaboration agreement in China
- Australian rights to use Enlitic as part of clinical partnership
- > 12 months of cash runway

# Strong outlook

- Strong underlying growth continuing
- Vic expected to continue to grow strongly during FY18
- Higher % growth in MRI – Capitol well positioned
- More stable regulatory environment

## DI Services and Revenues - Victoria 12M Rolling Growth Rates



Source: Medicare



# FY18 guidance upgrade

A\$m	FY18 (Nov Guidance)	FY18 (Feb Guidance)
Revenue Range	121 – 126	129 – 132
EBITDA Range	21.5 – 23.5	23.0 – 25.0

- High operational leverage and cost reductions to drive forecast EBITDA margin to ~19%+
- Strong underlying market and revenue growth circa 5% (corrected for working days)
- Assumptions include:
  - 2 months' contribution from NSW operations
  - 2 new clinics already opened, being VPH and Altona with benefit realised through FY19
  - Post-acquisition contributions from I-rad and Radiology Tasmania (not incl. in November guidance)
  - Further acquisition pipeline not included





# Disclaimer

- This presentation is the property of Capitol Health Limited (Capitol). This presentation is not and does not constitute an offer, invitation or recommendation to subscribe for, or purchase any security and neither this presentation nor anything contained in it shall form the basis of any contract or commitment.
- This presentation does not constitute an offer or invitation in any jurisdiction anywhere, or to any person to whom, such an offer would be unlawful. This presentation is not intended as an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in the United States or to any person to whom it is unlawful to make such an offer or solicitation. The securities that may be included in any offering have not been, and will not be registered under the US Securities Act.
- Reliance should not be placed on the information or opinions contained in this presentation. This presentation does not take into consideration the investment objectives, financial situation or particular needs of any particular investor. Any decision to purchase or subscribe for securities in Capitol must be made solely on the basis of the information contained in the in the public domain and if necessary, after seeking appropriate financial advice.
- No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, Capitol and its affiliates and related bodies corporate, and their respective officers, directors, employees and agents disclaim any liability (including, without limitation, any liability arising from fault or negligence) for any loss arising from any use of this presentation (or its content) or otherwise arising in connection with it.
- Capitol's forward-looking statements, intentions, forecasts, prospects, returns, expectations, statements in relation to future matters or other forward looking statement contained in this presentation may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. They are based on a number of estimates, assumptions that are subject to business, scientific, economic and competitive uncertainties and contingencies, with respect to future business decisions, which are subject to change and, in many cases, are outside the control of Capitol and its directors. Capitol does not undertake any obligation to revise or disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events. Neither Capitol nor its directors give any assurance that the forecast performance in the forecasts or any forward-looking statement contained in this presentation will be achieved.
- Except as otherwise expressly stated in this presentation, Capitol has not authorised any person to give any information or make any representation regarding the subject matter of this presentation.
- For these and other reasons, before undertaking any evaluation of Capitol, its assets, prospects or opportunities you are strongly recommended to obtain your own up to date independent legal, financial and commercial advice – those acting without such advice do so at their own risk.